Abstract Cannabinoids inhibit motility and secretion in the intestine. They are now assigned the additional task of curbing excessive inflammation, suggesting that drugs targeting the endogenous cannabinoid system could be exploited for inflammatory bowel disease....
Gastrointestinal (GI) disorders, including functional bowel diseases such as irritable bowel syndrome (IBS) and inflammatory bowel diseases such as Crohn’s disease and colitis, afflict more than one in five Americans, particularly women. While some GI disorders may be...
![Turned-Off Cannabinoid Receptor Turns on Colorectal Tumor Growth]()
Researchers find CB1 suppresses tumors, a new potential path for treatment & prevention New preclinical research shows that cannabinoid cell surface receptor CB1 plays a tumor-suppressing role in human colorectal cancer, scientists report in the Aug. 1 edition of...
Rochester, MN: The administration of synthetic THC (aka dronabinol) decreases colonic motility compared to placebo in patients with irritable bowel syndrome (IBS), according to clinical trial data to be published in the journal Gastroenterology. Investigators at the...
